Meanwhile, interval funds’ assets under management have grown almost 40% per year to $80 billion over the past 10 years through May 2024. Source: Morningstar Direct. Data as of May 31 ...

The findings demonstrate that AD disease activity remained mild in patients who had achieved treatment success and subsequently entered a treatment-free interval ... to see these data support ...

When Regeneron snagged an FDA nod for eye drug Eylea in diabetic retinopathy in 2019, the agency opted against approving a 16-week dosing schedule despite positive data from a pivotal trial.